How do I buy DiaMedica Therapeutics (DMAC) stock?

You can purchase shares of DiaMedica Therapeutics (NASDAQ:DMAC) through any online brokerage.View our list of the best stock brokerages

Who are DiaMedica Therapeutics (DMAC) competitors?

Other companies in DiaMedica Therapeutics’s space includes: Monopar Therapeutics Inc (NASDAQ:MNPR), Altimmune Inc (NASDAQ:ALT), Prothena Corp PLC (NASDAQ:PRTA), ADC Therapeutics SA (NYSE:ADCT) and Eupraxia Pharmaceuticals Inc (NASDAQ:EPRX).

What is the forecast, or price target, for DiaMedica Therapeutics (DMAC) stock?

DiaMedica Therapeutics has a consensus price target of $12.67.

What is the current price for DiaMedica Therapeutics (DMAC)?

The stock price for DiaMedica Therapeutics (NASDAQ: DMAC) is $8.41 last updated January 15, 2026 at 1:38 PM EST.

Does DiaMedica Therapeutics (DMAC) pay a dividend?

There are no upcoming dividends for DiaMedica Therapeutics.

When is DiaMedica Therapeutics (NASDAQ:DMAC) reporting earnings?

DiaMedica Therapeutics does not have any upcoming earnings scheduled.

Is DiaMedica Therapeutics (DMAC) going to split?

There is no upcoming split for DiaMedica Therapeutics.

What sector and industry does DiaMedica Therapeutics (DMAC) operate in?

DiaMedica Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

DiaMedica Therapeutics (DMAC) Stock Price, Quote, News & History

Bulls vs Bears

Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Name

Revenue

Change

Gross

Change

EBITDA

Change

EBIT

Change

Earnings

Change

About

Sector

Health Care

Industry

Biotechnology

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main prod...

Comments